SFRP1 and breast carcinoma: By stratifying the TCGA cohort by the breast cancer molecular subtypes, we noticed that the SFRP1 promoter was more methylated in luminal lesions compared to normal tissue (p-value < 0.0001; Figure S1D), which was coherent with SFRP1 decreased expression in luminal lesions compared to normal samples.